4.2 Article

Aberrantly expressed CEACAM6 is involved in the signaling leading to apoptosis of acute lymphoblastic leukemia cells

Journal

EXPERIMENTAL HEMATOLOGY
Volume 38, Issue 8, Pages 653-660

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.exphem.2010.03.018

Keywords

-

Funding

  1. Charles University (Prague, Czech Republic) [GAUK 7539/2007]
  2. Czech Ministry of Health (Prague, Czech Republic) [NS/10473-3]
  3. Ministry of Sports, Youth and Education (Prague, Czech Republic) [VZ MSMT 0021620813]

Ask authors/readers for more resources

Objective. The aberrant expression of myeloid antigens on acute lymphoblastic leukemia (ALL) cells is a well-documented phenomenon. So far, there have been no reports of a functional consequence of this aberrant expression. The granulocytic marker carcinoembryonic antigen related cell adhesion molecule 6 (CEACAM6, CD66c) is a GPI-anchored molecule that is reported to be the most frequently aberrantly expressed myeloid marker in ALL with a strong correlation with genotype. Materials and Methods. We mimicked CEACAM6 signaling in ALL cells by cross-linking with anti-CEACAM6 antibody. Next, we measured a response to CEACAM6 signaling by integrin subunits expression, integrin ligand binding, phosphorylation of extracellular signal-regulated kinase 1/2 (Erk1/2), Akt, and p38 mitogen-activated protein kinase (MAPK) and apoptosis by flow cytometry. Results. Following CEACAM6 cross-linking in ALL cells, we detected Erk1/2, Akt, and p38 MAPK phosphorylation and integrin upregulation, as well as enhanced binding of integrin ligands (vascular cell adhesion molecule-1 [VCAM-1] and intercellular cell adhesion molecule-1 [ICAM-1]). However, CEACAM6 signaling resulted in an increase in apoptosis, unlike other GPI-anchored molecules, such as CD24. Conclusion. The present study is the first to demonstrate the functional consequences of CEACAM6 cross-linking in B-cell precursor ALL cells. (C) 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Immunology

A Novel Case of Homozygous Interferon Alpha/Beta Receptor Alpha Chain (IFNAR1) Deficiency With Hemophagocytic Lymphohistiocytosis

Florian Gothe, Catherine F. Hatton, Linh Truong, Zofia Klimova, Veronika Kanderova, Martina Fejtkova, Angela Grainger, Venetia Bigley, Joanna Perthen, Dipayan Mitra, Ales Janda, Eva Fronkova, Dusana Moravcikova, Sophie Hambleton, Christopher J. A. Duncan

Summary: The case study presents a child with complete deficiency of the interferon alpha/beta receptor alpha chain (IFNAR1) who experienced fatal systemic hyperinflammation, possibly triggered by live-attenuated viral vaccination. This hyperinflammatory condition, meeting the criteria for hemophagocytic lymphohistiocytosis, is a new phenotype associated with inborn errors of type I interferon immunity.

CLINICAL INFECTIOUS DISEASES (2022)

Article Allergy

Early-onset pulmonary and cutaneous vasculitis driven by constitutively active SRC-family kinase HCK

Veronika Kanderova, Tamara Svobodova, Simon Borna, Martina Fejtkova, Vendula Martinu, Jana Paderova, Michael Svaton, Jarmila Kralova, Eva Fronkova, Adam Klocperk, Stepanka Pruhova, Min Ae Lee-Kirsch, Ludmila Hornofova, Miroslav Koblizek, Petr Novak, Olga Zimmermannova, Zuzana Parackova, Anna Sediva, Tomas Kalina, Ales Janda, Jana Kayserova, Marcela Dvorakova, Milan Macek, Petr Pohunek, Petr Sedlacek, Ashleigh Poh, Matthias Ernst, Tomas Brdicka, Ondrej Hrusak, Jan Lebl

Summary: This article reports a new monogenic autoinflammatory disorder caused by a de novo activating mutation in the HCK gene, characterized by cutaneous vasculitis and chronic pulmonary inflammation. The study shows the aberrant functions of mutant HCK and the therapeutic efficacy of the Janus kinase 1/2 inhibitor Ruxolitinib in treating inflammatory lung disease.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Article Hematology

TLR8/TLR7 dysregulation due to a novel TLR8 mutation causes severe autoimmune hemolytic anemia and autoinflammation in identical twins

Martina Fejtkova, Martina Sukova, Katerina Hlozkova, Karolina Skvarova Kramarzova, Marketa Rackova, David Jakubec, Marina Bakardjieva, Marketa Bloomfield, Adam Klocperk, Zuzana Parackova, Anna Sediva, Jahnavi Aluri, Michaela Novakova, Tomas Kalina, Eva Fronkova, Ondrej Hrusak, Hana Malcova, Petr Sedlacek, Zuzana Liba, Martin Kudr, Jan Stary, Megan A. Cooper, Michael Svaton, Veronika Kanderova

Summary: Our study identified a novel mutation c.1715G>T (p.G572V) in the Toll-like receptor 8 (TLR8) gene, which causes an autoimmune and autoinflammatory disorder in a family with monozygotic male twins. In vitro assays confirmed the pathogenicity of the mutation and revealed increased inflammatory responses.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Article Hematology

Either IL-7 activation of JAK-STAT or BEZ inhibition of PI3K-AKT-mTOR pathways dominates the single-cell phosphosignature of ex vivo treated pediatric T-cell acute lymphoblastic leukemia cells

Daniela Kuzilkova, Cristina Bugarin, Katerina Rejlova, Axel R. Schulz, Henrik E. Mei, Maddalena Paganin, Alessandra Biffi, Andrea Biondi, Tomas Kalina, Giuseppe Gaipa

Summary: This study utilized single-cell mass cytometry to investigate signal transduction pathways in T-cell acute lymphoblastic leukemia (T-ALL), and found that different cellular clusters exhibited varying responsiveness to therapeutic drugs, which remained consistent during relapse.

HAEMATOLOGICA (2022)

Letter Immunology

Impaired Humoral Response to Third Dose of BNT162b2 mRNA COVID-19 Vaccine Despite Detectable Spike Protein-specific T cells in Lung Transplant Recipients

Jan Havlin, Aneta Skotnicova, Eliska Dvorackova, Petr Hubacek, Monika Svorcova, Jan Lastovicka, Anna Sediva, Tomas Kalina, Robert Lischke

TRANSPLANTATION (2022)

Article Immunology

Standardization of Workflow and Flow Cytometry Panels for Quantitative Expression Profiling of Surface Antigens on Blood Leukocyte Subsets: An HCDM CDMaps Initiative

Daniela Kuzilkova, Joan Punet-Ortiz, Pei M. Aui, Javier Fernandez, Karel Fiser, Pablo Engel, Menno C. van Zelm, Tomas Kalina

Summary: This study developed a flow cytometric procedure for standardized quantitative expression profiling of surface antigens on blood leukocyte subsets across multiple research laboratories. The designed tubes can discriminate 27 leukocyte subsets and detect the expression of PE-conjugated CD markers.

FRONTIERS IN IMMUNOLOGY (2022)

Article Hematology

Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study

Sebastian Boettcher, Robby Engelmann, Georgiana Grigore, Paula Fernandez, Joana Caetano, Juan Flores-Montero, Vincent H. J. van der Velden, Michaela Novakova, Jan Philippe, Matthias Ritgen, Leire Burgos, Quentin Lecrevisse, Sandra Lange, Tomas Kalina, Javier Verde Velasco, Rafael Fluxa Rodriguez, Jacques J. M. van Dongen, Carlos E. Pedreira, Alberto Orfao

Summary: Reproducible expert-independent flow cytometric criteria for differential diagnoses between mature B-cell neoplasms were developed and validated using algorithm-driven classification. The diagnostic algorithm showed high accuracy and predictive values for various diseases, contributing to increased reproducibility in future diagnostics for mature B-cell neoplasms.

BLOOD ADVANCES (2022)

Review Immunology

Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain of Function (GOF) Mutations-10 Children and Review of the Literature

Angela Deya-Martinez, Jaques G. Riviere, Persio Roxo-Junior, Jan Ramakers, Marketa Bloomfield, Paloma Guisado Hernandez, Pilar Blanco Lobo, Soraya Regina Abu Jamra, Ana Esteve-Sole, Veronika Kanderova, Ana Garcia-Garcia, Mireia Lopez-Corbeto, Natalia Martinez Pomar, Andrea Martin-Nalda, Laia Alsina, Olaf Neth, Peter Olbrich

Summary: This study retrospectively examined pediatric patients with STAT1 GOF who received JAKinib treatment and found potential benefits of JAKinibs for this population. However, further research is needed to establish indications, dosing, and monitoring of JAKinibs.

JOURNAL OF CLINICAL IMMUNOLOGY (2022)

Letter Hematology

Hydrops fetalis and failure of hematopoietic stem cell transplantation - A long route to the diagnosis of SPTA1-associated hereditary spherocytosis

M. Svaton, M. Sukova, P. Sedlacek, A. Skotnicova, E. Vodickova, R. van Wijk, M. Divoka, R. Mojzikova, T. Kalina, J. Trka, E. Fronkova, J. Stary

BLOOD CELLS MOLECULES AND DISEASES (2022)

Article Immunology

Partial RAG deficiency in humans induces dysregulated peripheral lymphocyte development and humoral tolerance defect with accumulation of T-bet+ B cells

Krisztian Csomos, Boglarka Ujhazi, Peter Blazso, Jose L. Herrera, Christopher M. Tipton, Tomoki Kawai, Sumai Gordon, Maryssa Ellison, Kevin Wu, Matthew Stowell, Lauren Haynes, Rachel Cruz, Bence Zakota, Johnny Nguyen, Michelle Altrich, Christoph B. Geier, Svetlana Sharapova, Joseph F. Dasso, Jennifer W. Leiding, Grace Smith, Waleed Al-Herz, Mayra de Barros Dorna, Olajumoke Fadugba, Eva Fronkova, Veronika Kanderova, Michael Svaton, Sarah E. Henrickson, Joseph D. Hernandez, Taco Kuijpers, Snezhina Mihailova Kandilarova, Elizaveta Naumova, Tomas Milota, Anna Sediva, Despina Moshous, Benedicte Neven, Tara Saco, Ravishankar Sargur, Sinisa Savic, John Sleasman, Gauri Sunkersett, Brant R. Ward, Masanobu Komatsu, Stefania Pittaluga, Attila Kumanovics, Manish J. Butte, Michael P. Cancro, Shiv Pillai, Eric Meffre, Luigi D. Notarangelo, Jolan E. Walter

Summary: Patients with partial recombination-activating gene deficiency (pRD) exhibit late-onset autoimmune clinical phenotypes. This study found that pRD patients have a restricted primary B cell receptor repertoire enriched for autoreactivity and clonal persistence. Reduced RAG activity in pRD impairs peripheral tolerance through the generation of a restricted B cell repertoire and persistent antigenic stimulation. This results in widespread B cell dysregulation and activation.

NATURE IMMUNOLOGY (2022)

Article Oncology

Single-cell protein profiling defines cell populations associated with triple-negative breast cancer aggressiveness

Barbora Kvokackova, Radek Fedr, Daniela Kuzilkova, Jan Stuchly, Adela Vavrova, Jiri Navratil, Pavel Fabian, Robert Ondrussek, Petra Ovesna, Jan Remsik, Jan Bouchal, Tomas Kalina, Karel Soucek

Summary: Researchers have developed a comprehensive mass cytometry panel for the detection of phenotypic markers and signaling molecules in triple-negative breast cancer (TNBC). This single-cell proteomic approach allows for a better understanding of TNBC heterogeneity and the tumor microenvironment, and identifies potential therapeutic targets.

MOLECULAR ONCOLOGY (2023)

Article Allergy

Clinical Outcomes, Immunogenicity, and Safety of BNT162b2 Vaccine in Primary Antibody Deficiency

Tomas Milota, Jitka Smetanova, Aneta Skotnicova, Michal Rataj, Jan Lastovicka, Hana Zelena, Zuzana Parackova, Martina Fejtkova, Veronika Kanderova, Eva Fronkova, Katerina Rejlova, Anna Sediva, Tomas Kalina

Summary: Patients with CVID showed measurable antibody and T-cell immune responses after receiving the BNT162b2 vaccine, but the antibody titers were low and decreased rapidly, while the T-cell response remained stable. The vaccine demonstrated favorable safety and clinical outcomes in preventing severe COVID-19.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2023)

Article Hematology

Experience With IVDR Implementation in Three Diagnostic Laboratories: Messages to EU Health Institutions, Diagnostic Healthcare Payers, and Authorities

Bart R. Lubbers, Isabel Dombrink, Tomas Kalina, Mattias Hofmans, Morten S. Bruun, Simon J. Stanworth, Marie C. Bene, Konstanze Dohner, Monika Bruggemann, Elizabeth Macintyre, Jacques J. M. van Dongen

HEMASPHERE (2023)

Article Oncology

Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing

Petra Pokorna, Giannoula Lakka Klement, Alzbeta Vasikova, Veronika Kanderova, Marta Jezova, Kristyna Noskova, Peter Mudry, Michal Kyr, Tomas Merta, Viera Bajciova, Zdenka Krenova, Hana Palova, Dalibor Valik, Lenka Zdrazilova Dubska, Ondrej Slaby, Jaroslav Sterba

JCO PRECISION ONCOLOGY (2022)

No Data Available